Order from Huoshenshan Hospital！
? The sudden outbreak of COVID-19
At the end of 2019, the sudden outbreak of COVID-19 destroyed the festive atmosphere of Spring Festival. Since December, 2019, the newly detected 2019-nCoV poses a severe challenge to China’s public health system. As the disease progresses, varying degrees of hepatic impairment was discovered in many patients with COVID-19. Thus, a targeted treatment regimen is needed.
? Purchasing orders from Huoshenshan Hospital
The epidemic prevention and control can’t be delayed, neither can the medical supplies. Huoshenshan Hospital and Leishenshan Hospital, two emergency field hospitals for treating COVID-19 patients, undertook the mission of fighting against COVID-19. As the two hospitals went into service, numerous drugs used for epidemic prevention and control need to be distributed. On February 12, Trade Star received an order from Huoshenshan Hospital to purchase 5100 ampoules of Ademetionine 1,4-Butanedisulfonate for Injection.
? Why Ademetionine 1,4-Butanedisulfonate for Injection is purchased?
Recently, an article published in the Lancet indicates that among 99 COVID-19 patients, 43 presents varying degrees of hepatic impairment, including 1 case of sever hepatic impairment. In addition, abnormal liver function was observed in most patients, and it remains unclear whether it is induced by virus or by drugs.
Lan Fei research team, a team from liver cancer research institution of Zhongshan Hospital, Fudan University further explored the hepatic failure mechanism in COVID-19 patients. The findings, published in bioRxiv by this team on February 5, suggests that the abnormal liver function may be caused by a combination of bile duct cell dysfunction, drug, systemic inflammatory response and other factors instead of virus. In addition, the author advised that COVID-19 patients should be given special treatment for abnormal liver function during hospitalization and convalescence.
From wide view of therapeutic regimen and recent research findings of COVID-19, it was found that just like SARS, COVID-19 may cause abnormal liver function and that liver protection therapy is prerequisite.
It took Trade Star Pharmaceutical Co., Ltd and Zhejiang Zhenyuan Pharmaceutical Co., Ltd over ten years to develop Ademetionine 1,4-Butanedisulfonate for Injection—a blockbuster drug with hepatoprotective, cholagogic and systemic effect that is indicated for the treatment of abnormal liver function caused by drug-induced liver injury and liver inflammation. Therefore, it becomes a product used specially in patients with abnormal liver function during the treatment of COVID-19, it also becomes an urgently needed product during COVID-19 pandemic.
Considering the severity of the pandemic and the urgent need for the drugs, upon receiving order, Trade Star mobilized and coordinated various functional departments, including operation department, financial department, storage and transportation department, quality department. It took only one day to have all the drugs prepared and dispatched. Some may ask how we manage to do that during COVID-19 pandemic. It turns out that staff at Trade Star, with proper precaution, have been back to work since February 3 in case of unexpected demand. In the meanwhile, staff at Zhejiang Zhenyuan Pharmaceutical Co., Ltd worked overtime to ensure the supply as well as the quality. This batch of drugs can be put into use so rapidly relies not only on our willingness and ability to shoulder social responsibilities, but also on our staff who have been sticking to their posts.
Apart from being purchased by Huoshenshan Hospital, Ademetionine 1,4-Butanedisulfonate for Injection has also been listed in alternative procurement options for Leishenshan Hospital. We have been contributing our share to the fight against COVID-19.
? People’s health, our responsibility.
COVID-19 is not only a test for the overall innovative system and capacity of China’s medical system, but also a sever challenge to public health system and medical defense system. In the future, Trade Star will lay more emphasis on science, make breakthroughs, open arms to changes and make innovations. We will work hard to press ahead with the tenet of “cherish hope for humanity, devote to life and health”, striving to make even greater contributions to pharmaceutical industry.